Merck & Co Inc

• Merck raised full-year guidance following strong financial results and global demand. • Late-stage pipeline progress reinforced confidence in the company's growth strategy. • Analysts assigned an average price target of $157.01 with Buy ratings.

• Merck faced profit-taking despite strong third-quarter earnings and upgraded guidance. • Long-term growth concerns persist due to Keytruda's upcoming patent cliff. • Valuation scrutiny and inventory timing adjustments contributed to selling pressure.

• Gilead shares rose ahead of third-quarter financial results driven by therapy expectations. • Strategic pipeline updates and long-acting agents enhanced medium-term investor confidence. • Analysts raised price targets while technical indicators suggested buying conditions.

• Novartis upgraded its full-year core operating income outlook to growth. • Key therapeutic brands achieved double-digit expansion offsetting generic competition. • Technical indicators show a MACD buy signal and overbought conditions.

• Merck reported third-quarter revenue and earnings exceeding Wall Street estimates. • Keytruda strength and Winrevair sales growth drove financial performance. • Management raised full-year earnings guidance and refined sales targets.

• Eli Lilly reported strong third-quarter revenue and earnings exceeding Wall Street expectations. • Management raised its full-year revenue outlook driven by accelerating metabolic drug demand. • Technical indicators show strong buy signals alongside an extremely bullish market sentiment.